{
    "2021-12-06": [
        [
            {
                "time": "2021-12-06",
                "original_text": "医保谈判目录公布：国产创新药占比历年新高 首次关注高值罕见病创新药",
                "features": {
                    "keywords": [
                        "医保谈判",
                        "国产创新药",
                        "高值罕见病"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-12",
                "original_text": "医药行业2021年12月投资月报：业绩和政策真空期 医药板块有望持续反弹",
                "features": {
                    "keywords": [
                        "医药行业",
                        "投资月报",
                        "业绩",
                        "政策真空期",
                        "反弹"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-12-06",
                "original_text": "晚间重要公告2021年12月6日星期一",
                "features": {
                    "keywords": [
                        "晚间公告",
                        "12月6日"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-12",
                "original_text": "医药行业周报：医保谈判结果出炉 持续鼓励创新",
                "features": {
                    "keywords": [
                        "医药行业",
                        "医保谈判",
                        "结果",
                        "鼓励创新"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-12",
                "original_text": "深度揭秘2021年国家医保谈判结果",
                "features": {
                    "keywords": [
                        "国家医保",
                        "谈判结果"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-11",
                "original_text": "11月 恒瑞医药、再鼎医药、丽珠集团等达成新药授权合作",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "再鼎医药",
                        "丽珠集团",
                        "新药授权合作"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-12",
                "original_text": "恒瑞医药1类创新药海曲泊帕纳入2021年新版国家医保目录",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "创新药",
                        "海曲泊帕",
                        "医保目录"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-12",
                "original_text": "国金证券维持恒瑞医药买入评级：创新药全部纳入医保，即将迎来全面放量",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "买入评级",
                        "创新药",
                        "医保",
                        "全面放量"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-12",
                "original_text": "医药生物行业2022年展望：价值重鸣，创新为锋",
                "features": {
                    "keywords": [
                        "医药生物",
                        "2022展望",
                        "价值重鸣",
                        "创新为锋"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}